Lead clinical candidate CTX-187 is a novel antimicrobial immunotherapy developed to treat clinically-prevalent and multi-drug resistant Gram-negative bacterial infections -- Qualified Infectious ...

Antimicrobial resistance has become one of the greatest threats to public health, with rising resistance to carbapenems being a particular concern due to the lack of effective and safe alternative ...

Antibiotic resistance among Gram‐negative bacteria represents one of the most pressing challenges in modern medicine. These pathogens have evolved multiple mechanisms to evade the effects of ...

WHO’s director of antimicrobial resistance, Dr Yvan Hutin, says science needs to catch up with drug-resistant bacteria.

Multidrug-resistant gram-negative infections (MDRGNIs) are an emerging and deadly threat worldwide. Some of these infections are now resistant to nearly all antibiotics, and very few treatment options ...

Drugmakers must focus on developing new antibiotics to fight hospital “superbugs” including meningitis and other infections that can resist last-line treatments, the World Health Organization (WHO) ...

EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by ...

Urinary tract infections (UTIs) are common, but increasingly hard to treat because the bacteria that cause them are developing resistance to many antibiotics. Researchers headed by a team at the ...

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (“Appili”), an anti-infective drug development company, announced today that it will be receiving an additional $400,000 from the ...

Infections caused by gram-negative bacteria have features that are of particular concern. These organisms are highly efficient at up-regulating or acquiring genes that code for mechanisms of ...

Hospital uptake of newer antibiotics to treat multidrug-resistant gram-negative bacteria was low over a 5-year period, according to a retrospective cohort study. Fully 41.5% of episodes of ...